Search - tctmd.com

Displaying 321 - 340 of 477

Sort: Relevancy | Date

Presentation TCT 2014

The Data Strongly Support Bivalirudin!

Presenter: Gregg W. Stone

September 14, 2014

Presentation TCT 2014

The Data Strongly Support Heparin!

Presenter: Stefanie Schüpke

September 14, 2014

Presentation TCT 2014

The Data Strongly Support Bivalirudin!

Presenter: Roxana Mehran

September 14, 2014

Presentation TCT 2014

Position Statement: Heparin Will Once Again Become the Anticoagulant of Choice for PCI in Stable and Unstable Coronary Syndromes

Presenter: Kishore J. Harjai, Michael S. Lee

September 14, 2014

Presentation TCT 2014

Aspirin and ADP Antagonists Before and After Coronary Stent Implantation

Presenter: Paul A. Gurbel, Dmitriy N. Feldman

September 14, 2014

News Conference News TCT 2014

EUROMAX Substudy: Bivalirudin Noninferior to Heparin Plus GPI for Myocardial Reperfusion

September 14, 2014

News Conference News TCT 2014

TCT Course Director Outlines Current TAVR Controversies

September 14, 2014

Presentation TCT 2014

Role of New Oral Anticoagulants and New ADP Antagonists in ACS Patients

Presenter: Roxana Mehran, Mohamed Sobhy

September 13, 2014

Presentation TCT 2014

Antithrombin Therapy and GP IIb/IIIa Inhibitors in Patients with ACS and in Those Undergoing PCI

Presenter: Frederick Feit, Sripal Bangalore

September 13, 2014

Presentation TCT 2014

Optimal Duration of DAPT After Intracoronary Stenting: Current Status

Presenter: Roxana Mehran

September 13, 2014

Presentation TCT 2014

Are GP IIb/IIIa Inhibitors Still Useful?

Presenter: Marco Valgimigli

September 13, 2014

News Conference News TCT 2014

Meta-analysis: Less Bleeding, More Stent Thrombosis with Bivalirudin vs. Heparin After PCI

September 13, 2014

News Conference News TCT 2013

Regadenoson Shows Promise in Measuring Fractional Flow Reserve

November 07, 2013

News Conference News TCT 2013

Triple Antiplatelet Therapy with Cilostazol Increases Tachycardia, Arrhythmias

November 04, 2013

Presentation TCT 2013

The Conundrum of Switching DAPT

Presenter: Dean Kereiakes

October 31, 2013

Presentation TCT 2013

Shorter Is Better: New Insights From OPTIMIZE, PARIS, and Other Studies

Presenter: Roxana Mehran

October 31, 2013

Presentation TCT 2013

Prasugrel Rules: Simplest Second-Generation Agent with Fewest Side Effects!

Presenter: Michelle O'Donoghue

October 31, 2013

Presentation TCT 2013

Prasugrel Preloading in NSTEMI: ACCOAST Recap

Presenter: Gilles Montalescot

October 31, 2013

Presentation TCT 2013

Potential for Rivaroxaban Use in ACS and in the PCI Patient: Why Different Interpretations of the Same Data in the US and Europe?

Presenter: C. Michael Gibson

October 31, 2013

Presentation TCT 2013

Platelet Function Testing is of Clear Clinical Utility in Selected Patients

Presenter: Paul Gurbel

October 31, 2013

Advertisement

The Data Strongly Support Bivalirudin!

The Data Strongly Support Heparin!

The Data Strongly Support Bivalirudin!

Position Statement: Heparin Will Once Again Become the Anticoagulant of Choice for PCI in Stable and Unstable Coronary Syndromes

Aspirin and ADP Antagonists Before and After Coronary Stent Implantation

EUROMAX Substudy: Bivalirudin Noninferior to Heparin Plus GPI for Myocardial Reperfusion

TCT Course Director Outlines Current TAVR Controversies

Role of New Oral Anticoagulants and New ADP Antagonists in ACS Patients

Antithrombin Therapy and GP IIb/IIIa Inhibitors in Patients with ACS and in Those Undergoing PCI

Optimal Duration of DAPT After Intracoronary Stenting: Current Status

Are GP IIb/IIIa Inhibitors Still Useful?

Meta-analysis: Less Bleeding, More Stent Thrombosis with Bivalirudin vs. Heparin After PCI

Regadenoson Shows Promise in Measuring Fractional Flow Reserve

Triple Antiplatelet Therapy with Cilostazol Increases Tachycardia, Arrhythmias

The Conundrum of Switching DAPT

Shorter Is Better: New Insights From OPTIMIZE, PARIS, and Other Studies

Prasugrel Rules: Simplest Second-Generation Agent with Fewest Side Effects!

Prasugrel Preloading in NSTEMI: ACCOAST Recap

Potential for Rivaroxaban Use in ACS and in the PCI Patient: Why Different Interpretations of the Same Data in the US and Europe?

Platelet Function Testing is of Clear Clinical Utility in Selected Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content